When Does the Cost of Cancer Drugs Affect the Market?
Cancer's Bitter Medicine Alex Philippidis in today's Genetic Engineering News provides an excellent review of the treatment costs for CML (chronic myeloid leukemia) which can exceed $100k/year. However concern about the costs of cancer treatment has not yet hit the radar screen of major...
Rayno Life Science: Bringing on the Green After a Four Day Rest
Biopharmaceutical Stocks Rally- Many Rayno Picks up 2%+ If the past four days was the long awaited biotechnology correction it was barely noticeable, a mere 3.7% high to low over the past week.Today the rally has resumed with major large cap holdings from funds and ETFs for example : ALXN,...
Biotechnology Archives: Human Genome Sciences-Anthrax and Lupus
1999 Biotech Superstar Got Bailed Out By Anthrax antitoxin?! The famous Company that was going to revolutionize drug discovery was saved in 2003 by a government funded bioterror program for Anthrax and later a Lupus drug. Anthrax drug brings $334 million to Pentagon advisor's biotech firm -...
Major Sell-Off in Biopharmaceutical Stocks: Caution and Raise Cash -Update 1
Damage held to the AM-IBB Holds at $180 Two Volatile Stocks Green stocks in our coverage universe: ACHN, BIIB, CBST. Volume on all biotech stocks was above average, so review technicals as this could be a correction in the sector. We have not changed any of our biopharma picks but raise some...
Emerging Biomarker Companies Redux: BGMD,RGDX,VRML Positioned for Growth
Biomarker Products for Cardiovascular Disease and Cancer This is the third article on Emerging Biomarker Companies. See 11/15/12 Update The synergies between diagnostics and drugs are growing as more treatment options require better data for cost-effective, targeted therapeutics.The development...